Semaglutide
Semaglutide is a GLP-1 receptor agonist discussed for clinician-supervised weight-management pathways. Review centers on candidacy, titration, tolerability, contraindications, and continuity planning.
Not for emergencies. Call 911 if experiencing medical emergency.
Education
Explore clinician-guided education across metabolic care, recovery, Skin & Hair Health, Sexual Wellness, hormone support, and programs. Each page explains what the treatment is, where evidence is stronger or weaker, what risks matter, and what to review with a licensed clinician.
Semaglutide is a GLP-1 receptor agonist discussed for clinician-supervised weight-management pathways. Review centers on candidacy, titration, tolerability, contraindications, and continuity planning.
Tirzepatide is discussed as a dual GIP/GLP-1 pathway. New Blue frames the request around candidacy, current medications, side-effect tolerance, and how it compares with semaglutide.
Sermorelin is a GHRH analog discussed in growth-hormone-axis conversations. Claims around sleep, recovery, or body composition should stay conservative and individualized.
Tesamorelin is a stabilized GHRH analog. Evidence framing should distinguish its narrower approved-indication context from broader body-composition interest.
NAD+ is discussed because of its role in cellular energy metabolism, but stronger mechanistic interest does not automatically translate into strong human outcome data.
NAD+ nasal spray is a distinct intranasal request from injectable NAD+. New Blue reviews it as a prescription-required route option with conservative expectations.
Glutathione is discussed for antioxidant defense and redox balance. Route, intensity, convenience, and evidence limitations should be reviewed conservatively.
GHK-Cu is discussed as a topical peptide option for skin and hair support. Claims should remain practical, route-specific, and conservative.
Cashmere Cream is a prescription topical request. New Blue frames it around clinician review, skin history, current products, and realistic expectations.
Tadalafil 20 mg troche is reviewed as a sexual-wellness request with clinician screening, contraindication review, and clear term expectations.
Tadalafil 5 mg is an established once-daily dosing option for erectile dysfunction and benign prostatic hyperplasia. This 90-day request requires clinician review and does not guarantee treatment or any longevity outcome.
This platform offers PT-141 only to female-sexed patients with HSDD. Premenopausal HSDD is the FDA-approved indication; peri- or postmenopausal HSDD is off-label and requires documented clinician justification.
Injectable Testosterone Protocol is a clinician-reviewed hormone-health request. Treatment decisions depend on clinical history, labs, symptoms, contraindications, and clinician judgment.
Testosterone Cream Protocol is reviewed as a topical hormone-health request with lab context, symptom review, route preference, and safety considerations.
Oral Testosterone Protocol is reviewed as a hormone-health request where route fit, lab context, symptoms, and safety considerations drive the clinician decision.
Enclomiphene Hormone Support is reviewed as a hormone-health pathway. Fit depends on symptoms, labs, fertility goals, and clinician judgment.
Testosterone + hCG Support is a clinician-reviewed hormone-health request. Clinician review determines whether the components, route, and monitoring plan are appropriate.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
NAD+ + Glutathione is a program request for cellular-support discussions. Review should stay conservative and route-aware for both components.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
This program request combines hormone-health and GLP-1 review. Component fit depends on labs, symptoms, contraindications, medication history, and clinician judgment.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
A licensed clinician reviews the full program request and determines what is clinically appropriate. Included items describe what may be considered as part of the program; prescriptions are not guaranteed.
This guide is educational only. Peptide pathways require licensed clinician review, and compounded medications discussed through New Blue are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.